An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
The National Law Review40m
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
FDA says knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Ibj.com3h
Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
MIT Technology Review4h
Drugs like Ozempic now make up 5% of prescriptions in the US
US doctors write billions of prescriptions each year. During 2024, though, one type of drug stood out—“wonder drugs” known as ...
scrippsnews4h
FDA declares shortage over for popular weight-loss, diabetes drugs
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Hosted on MSN5h
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
24/7 Wall St6h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
kffhealthnews7h
FDA Confirms Shortage Over For Lilly’s Weight Loss Drugs; Copies Must Come Off Market
A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told ...